Cargando…

GABA(A) receptor subtypes and benzodiazepine use, misuse, and abuse

Benzodiazepines have been in use for over half a century. While they remain highly prescribed, their unfavorable side-effect profile and abuse liability motivated a search for alternatives. Most of these efforts focused on the development of benzodiazepine-like drugs that are selective for specific...

Descripción completa

Detalles Bibliográficos
Autor principal: Engin, Elif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879605/
https://www.ncbi.nlm.nih.gov/pubmed/36713896
http://dx.doi.org/10.3389/fpsyt.2022.1060949
_version_ 1784878728893956096
author Engin, Elif
author_facet Engin, Elif
author_sort Engin, Elif
collection PubMed
description Benzodiazepines have been in use for over half a century. While they remain highly prescribed, their unfavorable side-effect profile and abuse liability motivated a search for alternatives. Most of these efforts focused on the development of benzodiazepine-like drugs that are selective for specific GABA(A) receptor subtypes. While there is ample evidence that subtype-selective GABA(A) receptor ligands have great potential for providing symptom relief without typical benzodiazepine side-effects, it is less clear whether subtype-selective targeting strategies can also reduce misuse and abuse potential. This review focuses on the three benzodiazepine properties that are relevant to the DSM-5-TR criteria for Sedative, Hypnotic, or Anxiolytic Use Disorder, namely, reinforcing properties of benzodiazepines, maladaptive behaviors related to benzodiazepine use, and benzodiazepine tolerance and dependence. We review existing evidence regarding the involvement of different GABA(A) receptor subtypes in each of these areas. The reviewed studies suggest that α1-containing GABA(A) receptors play an integral role in benzodiazepine-induced plasticity in reward-related brain areas and might be involved in the development of tolerance and dependence to benzodiazepines. However, a systematic comparison of the contributions of all benzodiazepine-sensitive GABA(A) receptors to these processes, a mechanistic understanding of how the positive modulation of each receptor subtype might contribute to the brain mechanisms underlying each of these processes, and a definitive answer to the question of whether specific chronic modulation of any given subtype would result in some or all of the benzodiazepine effects are currently lacking from the literature. Moreover, how non-selective benzodiazepines might lead to the maladaptive behaviors listed in DSM and how different GABA(A) receptor subtypes might be involved in the development of these behaviors remains unexplored. Considering the increasing burden of benzodiazepine abuse, the common practice of benzodiazepine misuse that leads to severe dependence, and the current efforts to generate side-effect free benzodiazepine alternatives, there is an urgent need for systematic, mechanistic research that provides a better understanding of the brain mechanisms of benzodiazepine misuse and abuse, including the involvement of specific GABA(A) receptor subtypes in these processes, to establish an informed foundation for preclinical and clinical efforts.
format Online
Article
Text
id pubmed-9879605
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98796052023-01-27 GABA(A) receptor subtypes and benzodiazepine use, misuse, and abuse Engin, Elif Front Psychiatry Psychiatry Benzodiazepines have been in use for over half a century. While they remain highly prescribed, their unfavorable side-effect profile and abuse liability motivated a search for alternatives. Most of these efforts focused on the development of benzodiazepine-like drugs that are selective for specific GABA(A) receptor subtypes. While there is ample evidence that subtype-selective GABA(A) receptor ligands have great potential for providing symptom relief without typical benzodiazepine side-effects, it is less clear whether subtype-selective targeting strategies can also reduce misuse and abuse potential. This review focuses on the three benzodiazepine properties that are relevant to the DSM-5-TR criteria for Sedative, Hypnotic, or Anxiolytic Use Disorder, namely, reinforcing properties of benzodiazepines, maladaptive behaviors related to benzodiazepine use, and benzodiazepine tolerance and dependence. We review existing evidence regarding the involvement of different GABA(A) receptor subtypes in each of these areas. The reviewed studies suggest that α1-containing GABA(A) receptors play an integral role in benzodiazepine-induced plasticity in reward-related brain areas and might be involved in the development of tolerance and dependence to benzodiazepines. However, a systematic comparison of the contributions of all benzodiazepine-sensitive GABA(A) receptors to these processes, a mechanistic understanding of how the positive modulation of each receptor subtype might contribute to the brain mechanisms underlying each of these processes, and a definitive answer to the question of whether specific chronic modulation of any given subtype would result in some or all of the benzodiazepine effects are currently lacking from the literature. Moreover, how non-selective benzodiazepines might lead to the maladaptive behaviors listed in DSM and how different GABA(A) receptor subtypes might be involved in the development of these behaviors remains unexplored. Considering the increasing burden of benzodiazepine abuse, the common practice of benzodiazepine misuse that leads to severe dependence, and the current efforts to generate side-effect free benzodiazepine alternatives, there is an urgent need for systematic, mechanistic research that provides a better understanding of the brain mechanisms of benzodiazepine misuse and abuse, including the involvement of specific GABA(A) receptor subtypes in these processes, to establish an informed foundation for preclinical and clinical efforts. Frontiers Media S.A. 2023-01-12 /pmc/articles/PMC9879605/ /pubmed/36713896 http://dx.doi.org/10.3389/fpsyt.2022.1060949 Text en Copyright © 2023 Engin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Engin, Elif
GABA(A) receptor subtypes and benzodiazepine use, misuse, and abuse
title GABA(A) receptor subtypes and benzodiazepine use, misuse, and abuse
title_full GABA(A) receptor subtypes and benzodiazepine use, misuse, and abuse
title_fullStr GABA(A) receptor subtypes and benzodiazepine use, misuse, and abuse
title_full_unstemmed GABA(A) receptor subtypes and benzodiazepine use, misuse, and abuse
title_short GABA(A) receptor subtypes and benzodiazepine use, misuse, and abuse
title_sort gaba(a) receptor subtypes and benzodiazepine use, misuse, and abuse
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879605/
https://www.ncbi.nlm.nih.gov/pubmed/36713896
http://dx.doi.org/10.3389/fpsyt.2022.1060949
work_keys_str_mv AT enginelif gabaareceptorsubtypesandbenzodiazepineusemisuseandabuse